Company · CIK 1701541
Black Diamond Therapeutics, Inc.
| CIK | 1701541 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Business address | MA |
| Listed | BDTX (Nasdaq) |
| First annual or quarterly report | 2020-03-24 |
Offerings
4 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-291518 | 2025-11-13 | 2025-12-03 | 2 | |
| 333-268341 | 2022-11-14 | 2023-06-30 | 4 | |
| 333-252627 | 2021-02-01 | 2021-02-01 | 1 | |
| 333-235789 | 2020-01-03 | 2020-01-30 | 4 |
Filings
12| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2025-12-03 | EFFECTDeclared effective | 333-291518 | 9999999995-25-003511 |
| 2025-11-13 | S-3Shelf registered | 333-291518 | 0001104659-25-111490 |
| 2023-06-30 | 424B5Shelf takedown | 333-268341 | 0001104659-23-077054 |
| 2023-06-29 | 424B5Shelf takedown | 333-268341 | 0001104659-23-075983 |
| 2022-11-22 | EFFECTDeclared effective | 333-268341 | 9999999995-22-003381 |
| 2022-11-14 | S-3Shelf registered | 333-268341 | 0001193125-22-284590 |
| 2021-02-01 | S-3ASRShelf registered | 333-252627 | 0001193125-21-024779 |
| 2020-01-30 | 424B4Final prospectus | 333-235789 | 0001193125-20-019694 |
| 2020-01-29 | EFFECTDeclared effective | 333-235789 | 9999999995-20-000183 |
| 2020-01-21 | S-1/AAmendment | 333-235789 | 0001193125-20-010637 |
| 2020-01-03 | S-1Registration filed | 333-235789 | 0001193125-20-001336 |
| 2019-08-23 | DRSDraft made public | 377-02808 | 0000950123-19-008650 |